Image Sourced Shutterstock
Market Herald logo


Be the first with the news that moves the market
  • Nuheara has been approved as a registered provider to Australia’s National Disability Insurance Scheme
  • NDIS will enable Nuheara to support Autism in Australia
  • Positive results from the University of Melbourne supported to use of Nuheara’s IQBuds BOOST product

Nuheara has announced that it has been approved as a registered provider to Australia’s National Disability Insurance Scheme (NDIS) effective immediately.

Nuheara’s complete product range, which can be purchased with NDIS funding, will be available under the ‘Hearing Equipment’ category with the primary intention to support people with Autism.

The NDIS product approval process can be initiated directly from Nuheara’s website via an automated quotation process for NDIS workers, plan managers, or self-managers.

“Being listed on the NDIS places Nuheara at the centre of hearing health care beyond mild hearing loss,” Nuheara CEO Justin Miller commented.

“Our multifunctional products are supporting complex conditions that now allow us to expand to a much wider market than the traditional hearing aid/device industry,” he said.

According to Australian Autism body Amaze, Autism is continuing to be the largest diagnostic group within the NDIS with roughly 29 per cent of participants identifying as autistic.

People who are on the Autistic Spectrum Disorder often show difficulties with auditory processing.

The Centre for Auditory Neuroscience at the University of Melbourne has provided a preliminary report into its findings on the use of Nuheara’s IQBuds BOOST product.

While the study noted the subject numbers were small, there was significant improvement in auditory attention obtained.

The ability to concentrate in background noise has been identified as a key factor in influencing academic progress for children on the Autism Spectrum.

“We always wanted to expand our market scope but wanted to ensure this would be based on evidence-driven findings,” Justin added.

“Our preliminary results from an Autism study commissioned last year with the University of Melbourne have been positive,” he said.

The IQBuds BOOST delivers smart, personalised hearing when people don’t want to or can’t wear a hearing aid.

It includes Ear ID, which is a clinical hearing assessment that automatically calibrates the earbuds to a persons unique hearing profile.

While its primary objective is to enhance the wearer’s hearing, it also listens to audio streams, can make handsfree phone calls, and can connect to SIRI and Amazon equivalent, Alexa.

The potential now exists for IQBuds BOOST to expand in the global market.

NUH by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.